For low-resource internet-of-things (IoTs) like wearables, health-monitors, tags and sensors, existing authentication techniques (e.g., encryption, strong hash functions, pseudorandom number generators) might be impractical for securing access to critical data. This is because these devices have limited computational bandwidth; limited energy; and require real-time authentication. Static identifiers like bar-codes, product IDs, embedded physical unclonable functions (PUFs) or stored private keys are vulnerable to theft, counterfeiting, replay attacks or tampering. In this gap, Secure Dynamics is delivering enterprise-grade security solutions for energy-constrained Internet-of-things using zero-power timers. This solution uses zero-power timers to generate dynamic tokens that are secure against any power side-channel attacks, eaves-dropping and tampering. The hardware-software solution also supports mutual authentication, where the IoT device could also query and verify the trust of its reader.
Functional brain imaging is an important tool to assess brain health in conditions like stroke, cognitive function, visual function disorders, Parkinson’s, and ischemia. However, the MRI scanners are too bulky and expensive to bring the assessment where it is needed at the bedside or in ambulatory settings. EsperDyne's Wearable Optical Brain Imaging (WOBI) system addresses the cost and portability gap, bringing affordable functional brain imaging to the bedside and beyond. The market size for fNIRS Brain Imaging Systems is currently estimated at more than $135M with a CAGR of 10% as the systems gain additional research and clinical importance. The two known competing research systems lack the voxel density and portability of the WOBI system. The WOBI technology is protected by two issued and two pending US patents and has 3 prototype generations.
The logistics of ensuring compliance of thermal profiles (e.g., keeping cold items cold) for each product is a difficult problem. Solutions exist for monitoring temperature at coarse scale (shipping container), but those that precisely track each unit (color-changing stickers), lack the ability to precisely convey information in a scalable manner. Free Dynamics designs electronic temperature sensors that operate without any external batteries for months. Unlike current solutions, our quantum-mechanically-driven sensors are miniature and cost-effective enough to be incorporated into every vial of essential drugs that require stringent storage conditions. As a result, we can assure last-mile compliance while expecting higher accuracy. In addition, we have also shown that our system can be used for authentication which will guard the tagged assets against tampering and counterfeiting.
MedGyde develops ligand and antibody directed products which bind to antigens specific to various cancer subtypes. MedGyde’s pipeline includes antibodies and single-chain variable fragments which have demonstrated cytotoxic properties. The products have therapeutic as well as diagnostic applications (theranostic). MedGyde has also developed a radio-sensitization technology that targets and sensitizes cancer cells. The lead therapeutic antibody to inducible neoantigen, TIP1, binds specifically to cancer. It has been conjugated to both radiopharmaceuticals and chemotherapy which markedly improved cancer cures in pre-clinical cancer models. The planned clinical trial will be in patients with advanced non-small cell lung cancer. MedGyde has been awarded several NIH small business grants to further develop antibodies and nanoparticle drug delivery systems. Venture capital is needed for GMP manufacturing and IND enabling safety testing.
Non-invasive, accurate diagnosis and monitoring of prostate cancer through diffusion histology imaging. The technique has been validated with patient samples, demonstrates >95% agreement with pathologist-identified tumor stages, and can distinguish protest cancer from prostatitis or benign prostatic hyperplasia.
An implantable, bone-anchored sympathetic nerve stimulator that can be used for treatment of chronic pain, hypertension, asthma, hyperactive bladder, and many other conditions.
In endoscopic surgery, the surgeon often has to remove the endoscope and clean the lens in order to fully visualize the surgical procedure. This wastes time and puts the patient at risk. The rotoscope is a self-cleaning endoscope which minimizes surgical time and risk to the patient.
Coated sutures are designed for improved mechanical resilience to prevent failure of surgical repair. Unlike conventional sutures, which concentrate stress at the point of attachment, these sutures use an adhesive coating and soft adhesive zone to distribute stress along the length of the suture and reinstate load transfer across the tendon‐to‐bone repair.
Venohood is a custom cuff attachment to the venous end of an arteriovenous graft that reduces graft failure by lowering rate of thrombosis at the venous anastomosis. Venohood is founded by Prof. Mohamed Zayed, the co-founder and CMO of Caeli Vascular. Dr. Zayed is a rising star in fostering innovation at Washington University in St. Louis, with 8 new medtech inventions over the past 3 years. His disclosures have lead to four patent filings and one license to his startup, Caeli.
AIFEN is developing a two stent, fenestrated aorto-iliac endograft system for repairs in atherosclerotic occlusive diseases. AIFEN is founded by Prof. Mohamed Zayed, the co-founder and CMO of Caeli Vascular. Dr. Zayed is a rising star in fostering innovation at Washington University in St. Louis, with 8 new medtech inventions over the past 3 years. His disclosures have lead to four patent filings and one license to his startup, Caeli.
Cellulograft is developing an implantable device for cell replacement therapy that protects cells from immune attack. Cellulograft is founded by Prof. Mohamed Zayed, the co-founder and CMO of Caeli Vascular. Dr. Zayed is a rising star in fostering innovation at Washington University in St. Louis, with 8 new medtech inventions over the past 3 years. His disclosures have lead to four patent filings and one license to his startup, Caeli.
VaxNewMo’s goal is to be the next bioconjugate vaccine platform company. It is seeking a business co-founder to help shape a clinical development, fundraising, and partnership strategy that can maximize its impact and value
Gateway is an emerging privately held start - up addressing hearing loss and tinnitus. Incubated with BioGenerator in St. Louis, Gateway builds on research and clinical collaborations across several academic institutions including Washington University, Northeast Ohio Medical University and Harvard University. Its founders are scientific and clinical leaders in the field. Gateway has built a comprehensive research, discovery, and clinical development platform for new therapeutics to treat tinnitus and noise-induced hearing loss (NIHL). The platform is highly leveraged by federal funding, cumulatively some $30m of research by the scientific founder, and $12m in translational funding, including a Phase II hearing loss clinical trial funded by the U.S. Army. The Company has raised no equity capital to date.